Ginkgo Bioworks Holdings (NYSE: DNA), a synthetic-biology and autonomous-lab company, closed at $11.53 on October 14, 2026. Long/short manager Sean of Deep Sail Capital (@DeepSailCapital) said on October 12 that he had put on an industry short of genetic-data companies early the prior week, naming Tempus (TEM), CareDx (CDNA), Ginkgo (DNA) and Absci (ABSI). The DNA piece of that basket sits next to a business that just reported another sharp revenue drop while it pivots toward autonomous labs and AI biology.
This is journalism and commentary, not investment advice. We hold no position unless stated.
Key facts
- Ticker and exchange: Ginkgo Bioworks Holdings, DNA, NYSE.
- Situation type: Post-restructuring synthetic-biology platform shorted as part of a genetic-data industry basket.
- The call: Deep Sail Capital shorted DNA with TEM, CDNA and ABSI as a genetics/data theme, not as a one-name forensic short.
- Price: DNA closed at $11.53 on October 14, 2026, after trading near $13 when the basket post went up on October 12.
- Q2 2026: Revenue about $20 million, down 48% year over year; net loss from continuing operations about $57 million; adjusted EBITDA about negative $36 million.
- Cash: Management reaffirmed 2026 cash-burn guidance of $125 million to $150 million and cited roughly $302 million of cash plus $87 million of restricted cash entering the second half.
- Main risk for the short: National-lab and NSF-linked autonomous-lab contracts re-rate the stock before revenue recovers.
Is DNA a good bet right now?
The short case rests on cash burn and shrinking legacy revenue, not on a claim that autonomous labs are fake. After Ginkgo sold its biosecurity business in the first half of 2026, quarterly revenue fell to about $20 million. Management is explicit that 2026 is about cost efficiency plus investment in AI, robotics and software, and it guides investors to cash burn rather than revenue.
Bulls answer with infrastructure wins: remote access to Ginkgo's Boston Nebula lab under the NSF X-Labs program and other automation partnerships. Those headlines can move a small float even when trailing sales are weak. That is why a basket short can work or fail independently of any single press release.
Why are investors bearish on Ginkgo Bioworks?
- Revenue collapse after the pivot. Q2 2026 sales of about $20 million were roughly half the year-earlier level.
- Cash burn still large. Full-year 2026 burn guidance of $125 million to $150 million is the company's own preferred scoreboard.
- Theme risk. Deep Sail framed DNA with other genetic-data names that ran hard on AI-biology narratives.
- Need for proof. Analysts such as TD Cowen have described the autonomous-lab pivot as real but slow to show up in revenue timing.
Who's making this call and why?
Deep Sail Capital (@DeepSailCapital) is a long/short GARP fund account run by Sean, with about 57,000 followers on X. On October 12, 2026, responding to a question about shorts, he wrote, "I put on an industry short of genetic data companies early last week, $TEM, $CDNA, $DNA, and $ABSI". He had already flagged DNA on October 5 as "another genetics short too."
Track record. In our tracking, Deep Sail Capital is 13-12 (a .520 win rate) on 25 calls scored at 180 days against the S&P 500, with an average edge of +8.94 percentage points, ranking 4th on the career table. Shorts are 9-4 in that sample. See the scoreboard.
Other supporters:
- Dr Microcap (@MicrocapDr) said on October 11, "I'm short $DNA (Ginkgo Bioworks), and I've got call options as a backup," arguing a good short needs more than a high valuation.
Who disagrees?
- Company and partner headlines. Ginkgo has publicized autonomous-lab access for NSF X-Labs researchers and other automation work that bulls treat as proof the pivot is monetizing.
- Street price-target raises. A October 13 newswire noted TD Cowen raising a DNA price target to $11.00 from $9.00 even while the broader debate about timing continues.
- Retail bulls. Accounts following the Nebula and NSF story argue DNA is becoming "backbone" infrastructure for AI biology. Those posts are promotional in tone and should be weighed against the filings.
What are the key facts to verify?
- Q2 2026 revenue, cash, restricted cash and cash-burn guidance from Ginkgo's earnings materials.
- Terms and timing of NSF X-Labs / Nebula access and any national-lab automation contracts.
- Post-biosecurity segment mix and whether Solutions/Datapoints revenue is stabilizing.
- Dilution and refinancing risk around existing convertible notes as cash burn continues.
What would prove it right or wrong?
Signals the short thesis is working:
- Revenue stays near the low $20 million quarterly run-rate or falls again.
- Cash burn stays near the high end of the $125 million to $150 million guide.
- DNA underperforms other genetic-data names as the AI-biology narrative cools.
Signals it is failing:
- Bookings convert into a clear revenue ramp from autonomous labs.
- Cash burn falls faster than guided while cash stays ample.
- DNA rerate on contract wins even before quarterly sales recover.
This is journalism and commentary, not investment advice. We hold no position unless stated.